The prognostic significance of the triple negative phenotype in endometrial cancer

Gynecologic Oncology

Volumn 118, Issue 2, 2010, Pages 172-175

  Kothari, Rajul ^a   Morrison, Carl ^b   Richardson, Debra ^c   Seward, Shelly ^d   O'Malley, David ^e   Copeland, Larry ^e   Fowler, Jeffrey ^e   Cohn, David E ^e  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Endometrial cancer; Prognosis; Triple negative phenotype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE PHENOTYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; YOUNG ADULT;

EID: 77954244577     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.04.015     Document Type: Article

References (23)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, M.J. Thun. Cancer Statistics, 2009. CA Cancer J Clin 2009. Jul-Aug;59(4):225-49.
2. M.J. Horner, L.A.G. Ries, M. Krapcho, N. Neyman, and R. Aminou SEER cancer statistics review, 1975-2006 M.D. Bethesda, National Cancer Institute 2009 http://www.seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site
3. S. Kounelis, N. Kapranos, E. Kouri, D. Coppola, and H. Papadaki Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature Mod Pathol 13 4 2000 Apr 379 388
4. C. Morrison, V. Zanagnolo, N. Ramirez, D.E. Cohn, and N. Kelbick HER2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients J Clin Oncol 24 15 May 20 2006 2376 2385
5. T.A. Grushko, V.L. Filiaci, A.J. Mundt, K. Ridderstråle, O.I. Olopade, G.F. Fleming Gynecologic Oncology Group An exploratory analysis of HER2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 108 1 Jan 2008 3 9
6. M.A. Khalifa, R.S. Mannel, S.D. Haraway, J. Walker, and K.W. Min Expression of EGFR, HER2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas Gynecol Oncol 53 1 Apr 1994 84 92
7. V. Ludovini, S. Gori M. Colozza, L. Pistola, E. Rulli, et al. Ann Oncol. 2008 May;19(5):883-890
8. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008 May;19(5):883-890.
9. R. Ariga, A. Zarif, J. Korasick, V. Reddy, and K. Siziopikou Correlation of HER2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma Breast J 11 4 Jul-Aug 2005 278 280
10. R. Nishimura, and N. Arima Is triple negative a prognostic factor in breast cancer Breast Cancer Mar 2008 29
11. J. Reis-Filho, and A.N. Tutt Triple negative tumours: a critical review Histopathology 52 1 Jan 2008 108 118
12. E. Alli, V.B. Sharma, P. Sunderesakumar, and J.M. Ford Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase Cancer Res 69 8 Apr 15 2009 3589 3596
13. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple negative breast cancer (TNBC): Results of a randomized phase II trial. Presented at the 2009 annual meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL. Abstract P3.
14. J.M. Fowler, N. Ramirez, and D.E. Cohn Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis Am J Obstet Gynecol 192 4 Apr 2005 1262 1271
15. N. Shabani, C. Kuhn, S. Kunze, S. Schulze, D. Mayr, D. Dian, A. Gingelmaier, C. Schindlbeck, F. Willgeroth, H. Sommer, U. Jeschke, K. Friese, and I. Mylonas Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas Eur J Cancer 43 16 Nov 2007 2434 2444
16. K. Iwai, K. Fukuda, T. Hachisuga, M. Mori, M. Uchiyama, T. Iwasaka, and H. Sugimori Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma Gynecol Oncol 72 3 Mar 1999 351 359
17. K. Fukuda, M. Mori, M. Uchiyama, K. Iwai, T. Iwasaka, and H. Sugimori Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma Gynecol Oncol 69 3 Jun 1998 220 225
18. L.P. Pertschuk, S. Masood, J. Simone, J.G. Feldman, R.G. Fruchter, C.A. Axiotis, and G.L. Greene Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival Gynecol Oncol 63 1 Oct 1996 28 33
19. W.T. Creasman Prognostic significance of hormone receptors in endometrial cancer Cancer 71 4 Suppl Feb 15 1993 1467 1470
20. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 9 May 1 2007 1721 1728
21. T. Agurs-Collins, L. Rosenberg, K. Makambi, J.R. Palmer, and L. Adams-Campbell Dietary patterns and breast cancer risk in women participating in the Black Women's Health Study Am J Clin Nutr 90 3 2009 621 628 Sep
22. K.F. Trivers, M.J. Lund, P.L. Porter, J.M. Liff, E.W. Flagg, R.J. Coates, and J.W. Eley The epidemiology of triple-negative breast cancer, including race Cancer Causes Control 20 7 Sep 2009 1071 1082
23. E.A. Rakha, J.S. Reis-Filho, and I.O. Ellis Basal-like breast cancer: a critical review J Clin Oncol 26 15 May 20 2008 2568 2581